Assertio and Garda Mutually Delay Tender Offer Launch to May 14
Summary
Assertio Holdings and Garda Therapeutics have mutually agreed to delay the launch of the previously announced tender offer to acquire all outstanding shares of Assertio until May 14, 2026. This also postpones the tender offer for Assertio's Convertible Senior Notes to the same date. This procedural update follows the amended merger agreement announced on May 4, 2026, where Garda agreed to acquire Assertio for $21.80 per share in cash. While not a material change to the deal's terms, the delay provides a revised timeline for the acquisition process, which is important for investors tracking the transaction's completion. Traders should monitor for the tender offer launch and the associated Schedule 14D-9 filing around the new May 14th date.
At the time of this announcement, ASRT was trading at $22.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $144.2M. The 52-week trading range was $8.61 to $22.50. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.